HRP20191754T1 - Spojevi i postupci za antivirusno liječenje - Google Patents
Spojevi i postupci za antivirusno liječenje Download PDFInfo
- Publication number
- HRP20191754T1 HRP20191754T1 HRP20191754TT HRP20191754T HRP20191754T1 HR P20191754 T1 HRP20191754 T1 HR P20191754T1 HR P20191754T T HRP20191754T T HR P20191754TT HR P20191754 T HRP20191754 T HR P20191754T HR P20191754 T1 HRP20191754 T1 HR P20191754T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- nr11c
- nr11r12
- heterocyclyl
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261625480P | 2012-04-17 | 2012-04-17 | |
| EP13718996.5A EP2838900B1 (en) | 2012-04-17 | 2013-04-17 | Compounds and methods for antiviral treatment |
| PCT/US2013/037001 WO2013158776A1 (en) | 2012-04-17 | 2013-04-17 | Compounds and methods for antiviral treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191754T1 true HRP20191754T1 (hr) | 2020-01-24 |
Family
ID=48190648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191754TT HRP20191754T1 (hr) | 2012-04-17 | 2013-04-17 | Spojevi i postupci za antivirusno liječenje |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US8980878B2 (enExample) |
| EP (1) | EP2838900B1 (enExample) |
| JP (3) | JP2015516976A (enExample) |
| KR (2) | KR102181318B1 (enExample) |
| CN (2) | CN106986869A (enExample) |
| AU (1) | AU2013249280B2 (enExample) |
| CA (1) | CA2870024C (enExample) |
| CY (1) | CY1122292T1 (enExample) |
| DK (1) | DK2838900T3 (enExample) |
| EA (1) | EA027855B1 (enExample) |
| ES (1) | ES2750153T3 (enExample) |
| HK (1) | HK1209745A1 (enExample) |
| HR (1) | HRP20191754T1 (enExample) |
| HU (1) | HUE045727T2 (enExample) |
| IL (1) | IL235062A0 (enExample) |
| IN (1) | IN2014DN09173A (enExample) |
| LT (1) | LT2838900T (enExample) |
| MX (1) | MX355781B (enExample) |
| NZ (1) | NZ701647A (enExample) |
| PL (1) | PL2838900T3 (enExample) |
| PT (1) | PT2838900T (enExample) |
| SG (2) | SG10201610166VA (enExample) |
| SI (1) | SI2838900T1 (enExample) |
| WO (1) | WO2013158776A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8486938B2 (en) | 2010-06-24 | 2013-07-16 | Gilead Sciences, Inc. | Pyrazolo[1,5-a]pyrimidines for antiviral treatment |
| EP2794611B1 (en) | 2011-12-22 | 2017-10-11 | Gilead Sciences, Inc. | Pyrazolo[1,5-a]pyrimidines as antiviral agents |
| EA027855B1 (ru) * | 2012-04-17 | 2017-09-29 | Гайлид Сайэнсиз, Инк. | Соединения и способы для противовирусной терапии |
| EA038819B1 (ru) | 2013-08-21 | 2021-10-25 | Алиос Биофарма, Инк. | Противовирусные соединения |
| UA119151C2 (uk) * | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| WO2016055656A1 (en) * | 2014-10-10 | 2016-04-14 | Ablynx N.V. | Methods of treating rsv infections |
| EA032081B1 (ru) * | 2014-12-08 | 2019-04-30 | Янссен Сайенсиз Айрлэнд Юси | ЗАМЕЩЕННЫЕ ПИПЕРИДИНОМ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА С ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ РЕПЛИКАЦИИ РЕСПИРАТОРНО-СИНЦИТИАЛЬНОГО ВИРУСА (RSV) |
| WO2016091791A1 (en) * | 2014-12-08 | 2016-06-16 | Janssen Sciences Ireland Uc | Piperidine substituted tricyclic pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (rsv) |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| MA41614A (fr) | 2015-02-25 | 2018-01-02 | Alios Biopharma Inc | Composés antiviraux |
| JP2018076234A (ja) * | 2015-03-16 | 2018-05-17 | 大正製薬株式会社 | ピラゾロ［１，５−ａ］ピリミジン化合物 |
| JO3637B1 (ar) * | 2015-04-28 | 2020-08-27 | Janssen Sciences Ireland Uc | مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv |
| SG11201808907PA (en) | 2016-04-15 | 2018-11-29 | Blueprint Medicines Corp | Inhibitors of activin receptor-like kinase |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| MX390145B (es) | 2016-10-06 | 2025-03-20 | Orbus Therapeutics Inc | Formulaciones para la administracion de eflornitina |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| BR112020006334A2 (pt) | 2017-09-29 | 2020-09-24 | Enanta Pharmaceuticals, Inc. | combinação de agentes farmacêuticos como inibidores de rsv |
| JP7254821B2 (ja) * | 2017-10-16 | 2023-04-10 | ブリストル－マイヤーズ スクイブ カンパニー | 抗がん剤としての環状ジヌクレオチド |
| US11236086B2 (en) | 2017-10-18 | 2022-02-01 | Blueprint Medicines Corporation | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase |
| TW201932470A (zh) * | 2017-11-29 | 2019-08-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 具有抗ｒｓｖ活性之吡唑并嘧啶 |
| KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| KR20210005569A (ko) | 2018-04-23 | 2021-01-14 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Rsv에 대한 활성을 갖는 헤테로방향족 화합물 |
| CA3124783A1 (en) | 2018-12-27 | 2020-07-02 | Taisho Pharmaceutical Co., Ltd. | Pyrazolo[1,5-a]pyrimidine macrocyclic compound |
| JP7744350B2 (ja) | 2020-01-13 | 2025-09-25 | バージ アナリティクス，インコーポレイテッド | 置換ピラゾロ－ピリミジンおよびその使用 |
| WO2022092141A1 (ja) * | 2020-10-28 | 2022-05-05 | 塩野義製薬株式会社 | 抗ウイルス活性を有するアミド誘導体 |
| CN113264929B (zh) * | 2021-05-02 | 2023-10-10 | 润生药业有限公司 | 一种噻托溴铵的制备方法 |
| JP7454729B2 (ja) * | 2022-04-27 | 2024-03-22 | 塩野義製薬株式会社 | 抗ウイルス活性を有するアミド誘導体を含有する医薬組成物 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3361306A (en) | 1966-03-31 | 1968-01-02 | Merck & Co Inc | Aerosol unit dispensing uniform amounts of a medically active ingredient |
| US3565070A (en) | 1969-02-28 | 1971-02-23 | Riker Laboratories Inc | Inhalation actuable aerosol dispenser |
| FR2224175B1 (enExample) | 1973-04-04 | 1978-04-14 | Isf Spa | |
| US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
| IT1017153B (it) | 1974-07-15 | 1977-07-20 | Isf Spa | Apparecchio per inalazioni |
| SE438261B (sv) | 1981-07-08 | 1985-04-15 | Draco Ab | Anvendning i dosinhalator av ett perforerat membran |
| US4805811A (en) | 1985-03-29 | 1989-02-21 | Aktiebolaget Draco | Dosage device |
| SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
| US4955371A (en) | 1989-05-08 | 1990-09-11 | Transtech Scientific, Inc. | Disposable inhalation activated, aerosol device for pulmonary medicine |
| ES2284226T3 (es) | 1991-07-02 | 2007-11-01 | Nektar Therapeutics | Dispositivo para proporcionar medicamentos en aerosol. |
| US5261538A (en) | 1992-04-21 | 1993-11-16 | Glaxo Inc. | Aerosol testing method |
| US5388572A (en) | 1993-10-26 | 1995-02-14 | Tenax Corporation (A Connecticut Corp.) | Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same |
| US6342501B1 (en) | 1994-02-25 | 2002-01-29 | The Regents Of The University Of Michigan | Pyrrolo[2,3-d] pyrimidines as antiviral agents |
| US5543413A (en) | 1994-02-25 | 1996-08-06 | Regents Of The University Of Michigan | Heterocyclic thioamides and related analogs as antiviral agents with a unique mode of action |
| PL318199A1 (en) | 1994-06-29 | 1997-05-26 | Smithkline Beecham Corp | Antagonists of vitronectin receptors |
| US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
| US5544647A (en) | 1994-11-29 | 1996-08-13 | Iep Group, Inc. | Metered dose inhalator |
| US5622163A (en) | 1994-11-29 | 1997-04-22 | Iep Group, Inc. | Counter for fluid dispensers |
| CA2321153A1 (en) | 1998-02-17 | 1999-08-19 | Timothy D. Cushing | Anti-viral pyrimidine derivatives |
| US6116234A (en) | 1999-02-01 | 2000-09-12 | Iep Pharmaceutical Devices Inc. | Metered dose inhaler agitator |
| TWI225488B (en) | 1999-12-21 | 2004-12-21 | Janssen Pharmaceutica Nv | Derivatives of homopiperidinyl substituted benzimidazole analogues |
| WO2003037274A2 (en) * | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| WO2003078435A1 (en) | 2002-03-13 | 2003-09-25 | Pharmacia & Upjohn Company Llc | Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators |
| US7304068B2 (en) | 2002-05-10 | 2007-12-04 | Smithkline Beecham Corporation | Substituted pyrazolo [1,5-A] pyrimidinyls and pharmaceutical uses therefore |
| CA2487211C (en) | 2002-06-04 | 2010-09-14 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo(1,5a) pyrimidine compounds as antiviral agents |
| DE10247271A1 (de) | 2002-10-10 | 2004-08-26 | Grünenthal GmbH | Substituierte C-Imidazo[1,2-a]pyridin-3-yle |
| US8598193B2 (en) | 2003-12-24 | 2013-12-03 | Biota Scientific Management Pty Ltd. | Polycyclic agents for the treatment of respiratory syncytial virus infections |
| SG133452A1 (en) | 2005-12-30 | 2007-07-30 | Novartis Ag | Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases |
| US7517995B2 (en) * | 2006-04-06 | 2009-04-14 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-cyclopentapyrazole |
| US20070259855A1 (en) * | 2006-04-06 | 2007-11-08 | Udo Maier | Thiazolyl-dihydro-indazole |
| WO2008070447A2 (en) | 2006-11-21 | 2008-06-12 | Smithkline Beecham Corporation | Anti-viral compounds |
| US20090238772A1 (en) | 2007-12-13 | 2009-09-24 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for prevention or treatment of rsv infection |
| US20110052562A1 (en) | 2007-12-19 | 2011-03-03 | The Scripps Research Institute | Benzimidazoles and analogs as rho kinase inhibitors |
| BRPI0908529A2 (pt) | 2008-02-26 | 2015-09-29 | Novartis Ag | composto orgânicos |
| JP5637982B2 (ja) | 2008-04-09 | 2014-12-10 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 脂肪酸アミド加水分解酵素の阻害剤 |
| WO2010033701A2 (en) | 2008-09-19 | 2010-03-25 | Genzyme Corporation | Inhibitors of sphingosine kinase 1 |
| EP2182081B1 (de) | 2008-10-29 | 2014-01-22 | Neue Materialien Bayreuth GmbH | Verfahren zur thermischen Behandlung eines beschichteten Stahlblechkörpers |
| JP5762971B2 (ja) | 2008-12-03 | 2015-08-12 | プレシディオ ファーマシューティカルズ インコーポレイテッド | Ｈｃｖｎｓ５ａの阻害剤 |
| CA2746943A1 (en) | 2008-12-18 | 2010-07-15 | Boehringer Ingelheim International Gmbh | Serotonin 5-ht2b receptor inhibitors |
| MX2011006332A (es) | 2008-12-23 | 2011-06-27 | Abbott Lab | Compuestos antivirales. |
| TWI438200B (zh) * | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| CA2753382C (en) | 2009-02-27 | 2014-12-23 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2010101246A1 (ja) | 2009-03-05 | 2010-09-10 | 塩野義製薬株式会社 | Ｎｐｙ ｙ５受容体拮抗作用を有するピペリジンおよびピロリジン誘導体 |
| KR20100101054A (ko) * | 2009-03-07 | 2010-09-16 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
| PE20110679A1 (es) | 2009-06-11 | 2011-10-20 | Abbvie Bahamas Ltd | Derivados de (4-tert-butilfenil)pirrolidin-2,5-difenil como inhibidores del hcv |
| US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2010148006A1 (en) | 2009-06-16 | 2010-12-23 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| EP2462135A1 (en) * | 2009-08-07 | 2012-06-13 | Janssen R&D Ireland | Bis-benzimidazole derivatives as hepatitis c virus inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2011099832A2 (en) | 2010-02-12 | 2011-08-18 | Crystalgenomics, Inc. | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same |
| EP2575866A4 (en) * | 2010-05-24 | 2013-10-16 | Presidio Pharmaceuticals Inc | HCV NS5A INHIBITORS |
| US8486938B2 (en) | 2010-06-24 | 2013-07-16 | Gilead Sciences, Inc. | Pyrazolo[1,5-a]pyrimidines for antiviral treatment |
| SG186830A1 (en) * | 2010-07-22 | 2013-02-28 | Gilead Sciences Inc | Methods and compounds for treating paramyxoviridae virus infections |
| EP2794611B1 (en) | 2011-12-22 | 2017-10-11 | Gilead Sciences, Inc. | Pyrazolo[1,5-a]pyrimidines as antiviral agents |
| EA027855B1 (ru) | 2012-04-17 | 2017-09-29 | Гайлид Сайэнсиз, Инк. | Соединения и способы для противовирусной терапии |
-
2013
- 2013-04-17 EA EA201491889A patent/EA027855B1/ru not_active IP Right Cessation
- 2013-04-17 EP EP13718996.5A patent/EP2838900B1/en active Active
- 2013-04-17 HR HRP20191754TT patent/HRP20191754T1/hr unknown
- 2013-04-17 WO PCT/US2013/037001 patent/WO2013158776A1/en not_active Ceased
- 2013-04-17 HK HK15110629.1A patent/HK1209745A1/xx unknown
- 2013-04-17 NZ NZ701647A patent/NZ701647A/en not_active IP Right Cessation
- 2013-04-17 SG SG10201610166VA patent/SG10201610166VA/en unknown
- 2013-04-17 US US13/865,069 patent/US8980878B2/en active Active
- 2013-04-17 SG SG11201406736VA patent/SG11201406736VA/en unknown
- 2013-04-17 ES ES13718996T patent/ES2750153T3/es active Active
- 2013-04-17 JP JP2015507151A patent/JP2015516976A/ja active Pending
- 2013-04-17 DK DK13718996.5T patent/DK2838900T3/da active
- 2013-04-17 PT PT137189965T patent/PT2838900T/pt unknown
- 2013-04-17 KR KR1020207010642A patent/KR102181318B1/ko active Active
- 2013-04-17 HU HUE13718996A patent/HUE045727T2/hu unknown
- 2013-04-17 CN CN201710094970.6A patent/CN106986869A/zh active Pending
- 2013-04-17 LT LT13718996T patent/LT2838900T/lt unknown
- 2013-04-17 SI SI201331567T patent/SI2838900T1/sl unknown
- 2013-04-17 PL PL13718996T patent/PL2838900T3/pl unknown
- 2013-04-17 AU AU2013249280A patent/AU2013249280B2/en active Active
- 2013-04-17 MX MX2014012450A patent/MX355781B/es active IP Right Grant
- 2013-04-17 CA CA2870024A patent/CA2870024C/en active Active
- 2013-04-17 KR KR1020147030957A patent/KR102102283B1/ko active Active
- 2013-04-17 IN IN9173DEN2014 patent/IN2014DN09173A/en unknown
- 2013-04-17 CN CN201380030470.6A patent/CN104583211A/zh active Pending
-
2014
- 2014-10-07 IL IL235062A patent/IL235062A0/en unknown
-
2015
- 2015-03-02 US US14/635,830 patent/US9504689B2/en active Active
-
2016
- 2016-06-24 US US15/191,974 patent/US20170029427A1/en not_active Abandoned
-
2017
- 2017-03-21 JP JP2017054488A patent/JP6291103B2/ja active Active
- 2017-06-09 US US15/618,974 patent/US10174038B2/en active Active
-
2018
- 2018-02-08 JP JP2018020909A patent/JP2018095657A/ja not_active Withdrawn
-
2019
- 2019-11-14 CY CY20191101204T patent/CY1122292T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191754T1 (hr) | Spojevi i postupci za antivirusno liječenje | |
| HRP20160431T1 (hr) | Pirazolo[1,5-a]pirimidini i triazini kao antivirusni agensi | |
| EA201490419A1 (ru) | Соединения для лечения и профилактики респираторного синцитиального вирусного заболевания | |
| EP2658857A4 (en) | SUBSTITUTED PURIN NUCLEOSIDES, PHOSPHOROAMIDATES AND PHOSPHORODIAMIDATE DERIVATIVES FOR THE TREATMENT OF VIRUS INFECTIONS | |
| HRP20140370T1 (hr) | 1'-supstituirani-karba-nukleozid prolijekovi za antivirusni tretman | |
| JP2015506348A5 (enExample) | ||
| MY177898A (en) | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative | |
| JP2017537949A5 (enExample) | ||
| ES2572387T3 (es) | Compuestos anti-infecciosos | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| BR112013029862A2 (pt) | derivados de piridin-2 (1h)-ona úteis como medicamentos para o tratamento de distúrbios mieloproliferativos, rejeição a transplante, doenças imunomediadas e inflamatórias | |
| SI2709613T1 (en) | Procedures for the treatment of HCV | |
| GEP201706698B (en) | Inhibitors of influenza viruses replication | |
| BR112013030045A2 (pt) | composto da fórmula d-m-d ou um sal farmacêuticamente aceitável do mesmo; composto ou sal; composição farmacêutica; e método de tratamento de infecção por hepatite c em um paciente | |
| JP2016506962A5 (enExample) | ||
| MX2013008359A (es) | Aminas de c-28 de derivados de acido betulinico modificado de c-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana. | |
| HRP20110451T1 (hr) | Upotreba izotiocijanata kao sredstva protiv mieloma | |
| AR078766A1 (es) | Formas solidas de n-(4-(7-azabiciclo(2.2.1) heptan-7-il)-2-( trifluorometil) fenil)-4-oxo-5-(trifluorometil)-1,4- dihidroquinolina-3-carboxamida | |
| HRP20161742T4 (hr) | Soli i polimorfi od 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona | |
| AR086864A1 (es) | Derivados de polimixina utiles como agentes antibacterianos | |
| RU2014107484A (ru) | ПРИМЕНЕНИЕ СОЕДИНЕНИЙ 2,3-ДИГИДРОИМИДАЗО[1,2-с]ПИРИМИДИН-5(1H)-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ LP-PLA2 | |
| RU2015155289A (ru) | Гетероциклическое амидное соединение | |
| HRP20171050T1 (hr) | Derivati 1,3-dihidro-2h-benzimidazol-2-ona supstituirani s heterociklima kao antivirusna sredstva za respiratorni sincicijski virus | |
| ATE532787T1 (de) | Polycyclische mittel zur behandlung von infektionen mit dem respiratory syncytial virus | |
| RU2010151143A (ru) | Замещенные хиназолины |